NVAX
Novavax, Inc.
$10.11
+9.53%
2026-05-08
About Novavax, Inc.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Key Fundamentals
P/E Ratio
5.52
Forward P/E
-17.30
EPS (TTM)
$-0.56
Revenue Growth (YoY)
-79.1%
Profit Margin
-14.7%
Beta
2.37
Market Cap
$1.54B
Avg Volume (10D)
4.9M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$11.97
60D Low
$7.57
Avg Volume
4.4M
Latest Close
$10.11
Get breakout alerts for NVAX
Sign up for Breakout Scanner to receive daily notifications when NVAX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Novavax, Inc. (NVAX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors NVAX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. NVAX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.